Could cause temporary or reversible harm; serious harm is unlikely.
Presence of Particulate Matter.
| Brand name | LANREOTIDE ACETATE |
| Generic name | LANREOTIDE ACETATE |
| Active ingredient(s) | LANREOTIDE ACETATE |
| Distributed by / for | Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059 |
| NDC | 69097-870-67 |
| Full product label | Lanreotide Injection, 120 mg/0.5 mL, 0.5 mL per pre-filled syringe, For deep subcutaneous injection, Rx Only, Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059. NDC: 69097-870-67 |
| Recalling firm | Cipla USA, Inc. |
| Distribution | Nationwide in the USA |
| Quantity | 15,221 syringes |
| Recall initiated | 2026-01-02 |
| Report date | 2026-01-21 |
| Recall completed | — |
| Recall number | D-0290-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Warren NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗